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Since the implantation of the first artificial pacemaker in 1958, these devices have become the 
treatment of choice in bradycardias. Despite its widespread use, only a few studies have looked 
at the effects of single chamber right ventricular(RV) pacing on left ventricular(LV) function in 
patients with sinus node dysfunction or atrioventricular node dysfunction. In addition, these 
studies have produced conflicting results with no consensus reached. Furthermore, the 
limitation to these studies were the small sample sizes and the absence of sequential 
echocardiographic monitoring of LV function in each patient. To the best of the authors’ 
knowledge, no such studies have been conducted in South Africa.  
This study reviewed data collected from Inkosi Albert Luthuli Central Hospital (IALCH), which is 
a government hospital in Durban, KwaZulu-Natal (KZN), South Africa. The objective of the study 
was to evaluate the effects of RV pacing on LV function in a setting where the majority of 
patients requiring a permanent pacemaker receive single chamber RV apical pacing. The focus 
of this study was to assess the effect of RV pacing on LV function by assessing the ejection 
fraction(EF), on echocardiography, pre and post pacemaker insertion.   
A retrospective chart review of 465 patients managed at the IALCH pacemaker clinic from 2003 
up to 2012 was undertaken.  
Adult patients 18 years and older with a documented EF at the time of insertion of a pacemaker 
were included in the study.  
Patients were excluded from the study if they had coronary artery disease (CAD), unrepaired 
valvular heart disease, atrial fibrillation or dual chamber pacemakers. 
After enforcing the exclusion criteria, 430 patients were excluded and only 35 patients were 
eligible for the study. 
LV dysfunction was pre-defined as a left ventricular ejection fraction (LVEF) of < 50%. 
This study showed that RV pacing did not have a statistically significant effect on LV function 
post pacemaker insertion, based on the assessment of EF.  
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The study was limited by the low number of eligible patients as it was a retrospective study and 
obtaining data was difficult as most patients who require a pacemaker do not routinely have a 
baseline echocardiograph done prior to insertion of the pacemaker. Another limiting factor in 
the study was that EF was the only modality of LV function that was assessed. Moreover, 
evaluation of the EF on echocardiography is subjective and user dependent.  International 
studies have shown that the site of RV pacing has an impact on the degree of LV dyssynchrony 
and function.   This factor could not be assessed in the current study as the site of RV pacing 
was not documented and was not standardised.  
Pacing in the correct clinical context is a necessity and is lifesaving. Current literature shows 
that RV pacing is a safe, relatively simple, convenient procedure that is well tolerated and is 
effective. This study showed no deterioration in LV function in patients post RV pacemaker 
insertion, which is important as the RV remains the most common site of lead placement 
especially in the resource limited state sector. Some studies have reported that RV pacing is 
associated with LV dysfunction.  However, since there is a paucity of level 1 evidence regarding 
this aspect of RV pacing, the need for prospective studies on the long-term effects of RV pacing 
on LV function is required.  In addition, the impact of alternative pacing sites on LV function 
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Part 1: The Review of Literature 
 
THE EFFECTS OF RIGHT VENTRICULAR PACING ON LEFT VENTRICULAR FUNCTION 
1. Introduction: 
More than 1 million pacemakers and approximately 400 000 implantable cardioverter 
defibrillators (ICDs) are implanted worldwide each year. Although there remains a preference 
for single chamber ventricular pacing in developing countries, 70% of pacemakers presently 
implanted worldwide are dual-chamber systems.[1] 
Cardiac pacing is an effective treatment in the management of patients with bradyarrhythmias 
and tachyarrhythmias. It is the only effective treatment for patients with sick sinus syndrome 
and atrioventricular conduction disorders. Pacing of the right ventricle (RV) is a standard, 
widespread procedure because it is convenient, easily accessible, well-tolerated, effective and 
usually provides appropriate sensing and threshold parameters. [2,3] With the appearance of new 
indications for cardiac pacing which include patients with heart failure and left bundle branch 
block and the benefits of cardiac resynchronization therapy (CRT), the benefits of RV pacing has 
been questioned. There is increasing indirect evidence from international studies that RV pacing 
may have detrimental effects on (left ventricular) LV function.[1] LV dyssynchrony was found to 
be a critical factor in causing LV dysfunction. [4] 
However, the effects of RV pacing on LV function in KwaZulu-Natal (KZN) remain unclear as no 
local studies have been done to establish the effect of RV pacing on LV function. This is a 
concern because the RV is the most common site of pacemaker insertion in the state sector due 
to the lack of resources and skilled staff. 
This study set out to determine the effects of RV pacing on LV function by assessing the ejection 
fraction (EF) on echocardiography pre and post pacemaker insertion in the local South African 
context. A retrospective chart review of patients attending the Inkosi Albert Luthuli Central 
Hospital (IALCH) pacemaker clinic over a 10 year period was conducted.  
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In this paper we were able to show no statistically significant change in EF pre and post 
pacemaker insertion. 
2. History of cardiac pacing: 
In the 1920’s and 1930’s Dr Mark Lidwell of Australia and Dr Albert Hyman of the United States 
developed external cardiac pacemakers for clinical application. In 1958 the first internal cardiac 
pacemaker, designed by a Swedish team led by Ake Senning, a physician and Rune Elmqvist, an 
engineer was implanted in a patient with heart block. Over the next 3 decades a series of 
improvements and additions made the implantable devices more effective and reliable. In the 
early 1980’s several advances were reported which included the creation of the dual chamber 
pacemaker and the development of rate responsive devices. This made a great improvement in 
the quality of life and life expectancy.[5] 
3. Indications for cardiac pacing: 
Initially pacing had an exclusively palliative role for patients with heart block and severe 
symptomatic bradycardia.[3] Current pacing practice is undergoing continuous and substantial 
changes. Cardiac pacing is now the treatment of choice in severe and symptomatic 
bradycardia.[6] Cardiac pacing remains the only effective therapy for patients with sick sinus 
disease despite the early recognition that the stimulation of this site leads to an abnormal 
contraction pattern by bypassing the physiological conduction system. [3] Numerous studies 
have shown symptomatic and functional improvement by cardiac pacing of patients with 
atrioventricular blocks and in patients with chronic, drug-refractory atrial fibrillation.  Novel 
indications for cardiac pacing include drug-refractory heart failure and atrial fibrillation.[1,3] 
With the appearance of novel pacing indications, the effect of the pacing site on cardiac 
function has become a critically important issue. It seems like the classical pacing site in the RV 
is no longer the gold standard because of the possible disadvantageous effects on cardiac 
function. [3] 
4. Pathophysiology of RV pacing: 
Pacing at virtually any ventricular site disturbs the natural pattern of activation and contraction 
because conduction of the electrical wave front takes place slowly through ventricular 
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myocardium rather than through the His-Purkinje system.[7]This results in the electrical wave 
front propagating more slowly and this induces heterogeneity in electrical activation of the 
myocardium, comparable to left bundle branch block. This is characterized by a single 
breakthrough of the electrical wave form at the interventricular septum and subsequent 
delayed activation at the infero-posterior base of the LV.[2,7] 
Stimulation of the right ventricle leads to an abnormal electrical and mechanical activation 
pattern by bypassing the physiological conducting system. [3] It alters the electrical activation of 
the left ventricle and leads to dyssynchrony in left ventricular contraction, resulting in impaired 
haemodynamic function. [8] 
 
Clinical and experimental studies examining RV pacing observed that this technique caused a 
prolonged QRS duration, left ventricle asymmetrical hypertrophy, dilatation, remodeling, mitral 
valve regurgitation, altered myocyte histology, reduced exercise capacity and coronary 
perfusion abnormalities. [4]  
 
More than 80 years ago, it was shown that ventricular pacing results in adverse haemodynamic 
consequences in mammals. This finding has been replicated in numerous animal experiments 
and more recently in human patients. From these studies, the cause of the reduction in pump 
function was shown to be asynchronous electrical activation.[7] 
The RV apex has become the most common site for placement of the pacemaker lead. The RV 
apex is convenient and easy for the implanter to reach and yields stable mechanical positions 
and stimulation thresholds.[7] 
Similar to the changes in electrical activation of the ventricles, the mechanical activation 
pattern of the LV is changed during RV apical pacing. Importantly, it disrupts the onset and the 
pattern of mechanical contraction of the LV. Several animal studies have demonstrated that the 
early activated regions near the pacing site exhibit rapid early systolic shortening, resulting in 
pre-stretch of the late-activated regions. The affected regions exhibit an increase in (delayed) 
systolic shortening, imposing systolic stretch to the early activated regions exhibiting premature 
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relaxation. This abnormal contraction pattern of the various regions of the LV may result in a 
redistribution of myocardial strain and work and subsequent less effective contraction.[2] 
Both the abnormal electrical and mechanical activation pattern of the ventricles can result in 
changes in cardiac metabolism and perfusion, remodeling, haemodynamics, and mechanical 
function. Even in the absence of coronary artery disease, myocardial perfusion defects may be 
present in up to 65% of the patients after long-term RV apical pacing and are mainly located 
near the pacing site.[2] 
The table below taken from Laurens et al [2] summarises the effects of RV apical pacing. 
Acute and Long-Term Effects of RV Apical Pacing [2] 
Changes in electrical activation and mechanical activation 
Metabolism/perfusion 
 Changes in regional perfusion 
 Changes in oxygen demand 
Remodeling 
 Asymmetric hypertrophy 
 Histopathological changes 
 Ventricular dilation 
 Functional mitral regurgitation 
Haemodynamics 
 Decreased cardiac output 
 Increased LV filling pressures 
Mechanical function 
 Changes in myocardial strain 
 Interventricular mechanical dyssynchrony 




5. Clinical Implications of RV pacing: 
 
 
The above figure 1 taken from AM Gillis[1] highlights the mechanisms by which RV apical pacing 
causes heart failure and atrial fibrillation. 
RV pacing has been shown to cause heart failure symptoms with and without previous systolic 
left ventricular dysfunction.[9] Unfortunately, the exact amount of RV apical pacing that 
negatively affects cardiac function remains unclear from the trials. A certain amount of 
ventricular pacing may actually be physiologically beneficial because it maintains atrio-
ventricular conduction.  At the same time, the negative effects of RV apical pacing may be more 
pronounced in certain patient populations. In particular, patients with underlying conduction 
disease and patients with ischaemic heart disease may be at risk. Furthermore, it has been 
suggested that patients who require pacing for a longer period of time and patients with 
depressed LV function at baseline are more susceptible to the deleterious effects of RV apical 
pacing. More studies are therefore needed to fully understand the beneficial and deleterious 
effects of RV apical pacing and to better identify the patients who are at risk for the detrimental 





6. Pacing sites: 
The effect of the pacing site on cardiac function has become a critically important issue and a 
subject of consideration since the appearance of new indications for cardiac pacing, which 
include heart failure and atrial fibrillation.[3]  The ventricular pacing site has a major effect on LV 
function. The optimal pacing lead location for patients with a standard indication for ventricular 
pacing remains controversial.[4]From the larger pacing mode selection trials and the 
observational studies, there is a clear association between conventional right ventricular pacing 
and the risk of adverse events. However, in daily clinical practice not all patients who receive 
right ventricular pacing will experience adverse events. [2] 
The RV apex is the preferred site of RV lead placement because of the ease of implantation and 
the low risk of lead dislodgement.[1] However, pacing of the RV apex can alter the electrical LV 
activation sequence and lead to dyssynchrony in LV contraction, resulting in impaired 
haemodynamic function.[8] There is growing evidence to support that LV free wall pacing and 
not RV apical pacing improves LV contraction in patients with heart failure and intraventricular 
conduction delays.[10]  
The potential benefit of pacing from non-right ventricle apical sites that can theoretically 
closely simulate the normal cardiac electrical activation sequence needs to be explored 
further.[10] It is still unclear why some patients acutely develop ventricular dyssynchrony and 
others do not. This may be due to the subtle differences in the location of the pacing lead 
within the RV apex, and thus the proximity to the Purkinje system. Echocardiographic 
techniques used to assess ventricular dyssynchrony may not be sensitive enough to detect 
small changes in electromechanical activation. Therefore, larger and longer term clinical trials 
are needed to identify the optimal pacing site.[2] 
Pacing from the right ventricle outflow tract, septal pacing and direct His bundle pacing have 
been suggested as alternative pacing sites as they are in closer proximity to the normal 
conduction system and may result in less electrical activation delay and less mechanical 




7. Important Clinical Trials: 
 
The following supplementary table has been taken from AM Gillis [1]  
Table 1: 
Study Patients Design Outcomes 
DAVID11 506 patients with 
ICD indication  
Prospective 
randomized  
DDDR lower rate 
70bpm vs Backup 
VVI pacing lower 
rate 40bpm 
1.61 increased relative risk of death 









DDDR vs VVIR 
pacing 
Cumulative % VP > 40% in DDDR 
mode associated with 2.8 fold risk of 
HF hospitalization; cumulative % VP 
> 80% in VVIR mode associated with 
2.5 fold risk of HF hospitalization; 
risk of developing AF increased by 
0.7% or 1% for each 1% increment in 
cumulative % VP up to 80% in VVIR & 

















Median % VP 9.1 vs 99% in DDDR 
with minimal VP algorithms vs 
conventional DDDR; 40% reduction 
in relative risk of AF in DDDR group 
with algorithms to reduce VP 
compared to conventional DDDR.  
PACE14 177 patients 
Bradycardia 
pacing indication 
LVEF ≥ 45% 
Prospective 
randomized 
BiV vs DDDR pacing 
LVEF lower in DDDR vs BiV-pacing 
group 954.8+/-9.1% vs 62.2+/-7%, 
P<0.001) 
No difference in HF events  
BLOCK HF15 691 patients 
High grade AV 
block pacing 
LVEF ≤ 50% 
Prospective 
randomized 
BiV vs RV apical 
pacing (pacemaker 
or ICD based on 
clinical indications) 
Significant reduction in primary 
outcome (composite endpoint of 
death, urgent HF visit requiring 
intravenous drug therapy or ≥ 15% 
increase in LVESV index) in BiV group 
compared to RV pacing group 
MADIT16 567 ICD patients 




During late phase of extended 
follow-up mortality increased in 
patients with % RV pacing > 50% 




SND – sinus node disease 
BiV – biventricular 
LBBB – left bundle branch block 
VP – ventricular pacing 
 
It is important to emphasize that the adverse outcomes reported in the table have been 
dependent on a high cumulative percentage of RV pacing, generally more than 40%.[12,17,18] 
Furthermore, the increased risk of heart failure reported has been predominantly observed in 
those with pre-existing LV systolic dysfunction.[1] 
The data that indicates that RV pacing causes heart failure over time in patients with a normal 
baseline LV function is extremely weak. [1] The Danish Multicenter Randomized Trial on Single 
Atrial Lead Pacing versus Dual Chamber Pacing in Sick Sinus Syndrome (DANPACE) study looked 
at patients with sinus node dysfunction and showed no correlation between the development 
of heart failure and RV pacing. Furthermore, although adverse LV remodelling characterized by 
LV chamber enlargement and reduction in LVEF has been described in some patients with 
congenital complete heart block after pacemaker implantation, the majority of these patients 
did not develop changes in systolic function nor did they develop symptomatic heart failure 
when followed up for prolonged periods of time.[1] 
There is conflicting data regarding the differences between RV and biventricular pacing on the 
LV function. 
The Preventing Ventricular Dysfunction in Pacemaker Patients without Advanced Heart Failure 
(PREVENT – HF) study was the first randomized controlled multi-centre trial comparing 
conventional RV versus biventricular pacing in patients with atrioventricular block who need 
bradycardia support. This study did not demonstrate significant LV volume differences between 
RV apical and biventricular pacing in patients who had been diagnosed with atrio-ventricular 
block and had been paced for more than 12 months.[19] 
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The Biventricular Pacing for Atrio-ventricular Block to Prevent Cardiac Desynchronization 
(BIOPACE) study concluded that there was a statistically insignificant difference between 
biventricular and RV pacing in patients with atrio-ventricular block who needed implantation of 
a permanent pacemaker.[20] 
The Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular 
Block (BLOCK-HF) trial randomised patients with atrio-ventricular block, New York Heart 
Association (NYHA) symptom class I-III heart failure, and LVEF ≤50% to biventricular or RV 
pacing. This study showed that cardiac structure and function improved with biventricular 
pacing for patients with atrio-ventricular block and LV systolic dysfunction. However, this trial 
was greatly limited by the inclusion of patients with EF of less than 30%.[20] 
A sub-study of the Mode Selection Trial (MOST) demonstrated a strong association between 
right ventricular pacing and the risk of heart failure hospitalisation and atrial fibrillation in 
physiological pacing and ventricular pacing.[2] 
It has been suggested that patients with moderate to severe LV dysfunction and a standard 
pacemaker indication may actually benefit from CRT instead of RV apical pacing alone.[2] A 
number of observational studies and randomized trials have performed a head-to-head 
comparison between the 2 pacing modes. These studies have been summarised in the table 
below. 
Randomized Clinical Trials Comparing RV Apical Pacing Versus CRT [2] 
Table 2: 





MUSTIC [21] 43 Crossover Chronic heart 
failure 
LV systolic 
6MWT Peak Vo2 
QOL 
Heart failure 
CRT modestly superior 
over RV pacing for 
6MWT and peak Vo2 
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QRS >200 ms 





No difference in QOL 







 • QOL 
 • 6MWT 
CRT modestly superior 
over RV pacing for QOL 
and 6MWT 
PAVE [23] 184 Parallel 
arms 




CRT superior over RV 
pacing for 6MWT and 
LVEF 
No differences in QOL 













CRT superior over RV 
pacing for LVESV, LVEF, 
peak Vo2 
CRT superior over RV 















LVEF LV dyssynchrony 
LV diastolic 
function 
 • LA volumes 
 • LV dimensions 
 • NT-proBNP 
 • 6MWT 
No difference in LVEF 
No differences in 
secondary end points 
AF = atrial fibrillation; AV = atrioventricular; AVN = atrioventricular node; CRT = cardiac resynchronization therapy; HOBIPACE = 
Homburg Biventricular Pacing Evaluation; LA = left atrial; LVESV = left ventricular end-systolic volume; MUSTIC = Multisite 
Stimulation in Cardiomyopathies Study; NT-proBNP = N-terminal pro–B-type natriuretic peptide; OPSITE = Optimal Pacing SITE; 
PAVE = Left Ventricular-Based Cardiac Stimulation Post AV Nodal Ablation Evaluation; PM = pacemaker; AVB = atrioventricular 
block; AVJ = atrioventricular junction; BNP = B-type natriuretic peptide; CRT = cardiac resynchronization therapy; ECG = 
electrocardiogram; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; NYHA = New York Heart 
Association; QOL = quality of life; QRS = QRS complex; SND = sinus node dysfunction; 6MWT = 6-min walk test; Vo2 = maximal 
oxygen uptake 
In the Homburg Biventricular Pacing Evaluation (HOBIPACE) trial, 30 patients with standard 
indications for permanent pacing and an LVEF ≤40% were randomized between RV pacing and 
CRT. After 3 months of pacing, crossover to the other pacing modality was performed. The LV 
end-systolic volume was 177.3 ± 68.7 ml at baseline and decreased modestly with RV pacing 
(160.2 ± 73.4 ml, p < 0.05). When compared with RV pacing, CRT significantly reduced LV end-
systolic volume by 17% (133.1 ± 66.5 ml, p < 0.001). [24] 
Although some trials have demonstrated a clear long-term benefit of CRT over RV pacing with 
regard to peak VO2 or the distance walked during the 6-min walk test, others have 
demonstrated only modest or no benefit at all. [2,22,24] 
In developing countries such as South Africa, RV pacing still remains the most common choice 




8. Rationale for this study: 
From the large pacing mode selection trials and observational studies, it has become apparent 
that a considerable amount of RV pacing may be associated with a worse clinical outcome. 
Unfortunately, it remains unclear if there is an “optimal amount” of RV pacing and which 
patients are most susceptible to the deleterious effects of RV pacing. The negative effects may 
be related to the induction of ventricular dyssynchrony by RV apical pacing. Future studies are 
needed to address these remaining questions.[2] Additional analyses will perhaps identify 
cohorts of patients for whom biventricular pacing would confer a clear benefit. 
All the literature is from studies done abroad and limitations to these studies were the small 
sample sizes and the absence of sequential echocardiographic monitoring of the LV function in 
each patient.  
RV pacing is an important tool in the South African context, where resources and skilled staff 
are limited. This study attempted to elucidate the local South African experience by evaluating 
the effects of RV pacing on LV function by assessing the EF on echocardiography in patients 
attending the pacemaker clinic at IALCH from 2003 to 2012. 
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Pacing of the right ventricle has become a standard, widespread procedure. In recent years, the 
potential detrimental effects of RV pacing have been studied with one of the complications being 
the deterioration of the left ventricular ejection fraction (EF) as a direct result of RV pacing.  
 
Objective 
To evaluate the effects of RV pacing on LV function by assessing the EF on echocardiography, 
pre- and post- pacemaker insertion, at Inkosi Albert Luthuli Hospital (IALCH), a government 
hospital in Durban, KwaZulu-Natal(KZN). 
 
Methods 
A retrospective chart review of 465 patients managed at IALCH pacemaker clinic from 2003 up 
to 2012 was undertaken. Adult patients 18 years and older with a documented EF pre- and post-
RV pacemaker insertion were included. Patients were excluded if they had coronary artery 
disease (CAD), unrepaired valvular heart disease, atrial fibrillation or dual chamber pacemakers. 
RV pacing was performed through insertion of a lead in the subclavian vein with placement of 
the sensing and pacing electrode in the RV apex. The EF was measured using 2D 
echocardiography and calculated using the Simpsons method. LV dysfunction was defined as an 
EF <50%. 
 
The Intercooled Stata Version 13 Package was used to analyse the data. Descriptive statistics 
were used to present categorical variables. The mean and standard deviation were used to 
analyse continuous variables and the percentages of frequencies. Two group comparisons were 
made using a two sample t test. The two sample t test was used to calculate the change in the EF 
between baseline and follow-up. The Kruskal Wallis equality test was used to assess categorical 
variables when comparing more than two subgroups due to the small study numbers.  A p value 






Of the 465 patients screened, 35 patients satisfied the inclusion criteria with pre- and post- 
pacemaker insertion ejection fractions. The mean age was 62 years. Complete heart block (57%) 
and second degree heart block (20%) were the main indications for pacing. The VVI pacing 
mode was applied to majority (54%) of the patients.  The study did not show any significant 
decline in the LVEF in patients with RV pacing, p= 0.10. Age and gender had no impact on the 
LVEF. Similarly, hypertension, diabetes mellitus, dyslipidaemia and valve repair had no 
significant impact on the LVEF. 8 patients had LV dysfunction at baseline, of these 1 had a 
deterioration in EF from 42% to 36%, 2 remained the same and 5 showed a mean increase in EF 
of 5.4% between baseline and follow-up, p = 0.03. 
 
Conclusion 
This study showed no significant change in EF following pacemaker insertion. This is important 










RV – right ventricle/ ventricular 
LV – left ventricle/ ventricular 
IALCH – Inkosi Albert Luthuli Hospital 
KZN – KwaZulu-Natal 
EF – ejection fraction 
CRT - cardiac resynchronization therapy 
CAD – coronary artery disease 
LVEF – left ventricular ejection fraction 















Pacing of the right ventricle has become a standard, widespread procedure because it is 
convenient, easily accessible, well-tolerated, effective and usually provides appropriate sensing 
and threshold parameters. [1,2] Despite its widespread use, only a few studies have looked at the 
effects of single chamber right ventricular(RV) pacing on left ventricular(LV) function in 
patients with sinus node dysfunction or atrioventricular node dysfunction.[3] In addition, these 
studies have produced conflicting results with no consensus reached. Furthermore, the limitation 
to these studies were the small sample sizes and the absence of sequential echocardiographic 
monitoring of LV function in each patient. In recent years, the potential detrimental effects of RV 
pacing have been studied and LV dyssynchrony has been shown to be a critical factor in causing 
LV dysfunction. [4] 
To the best of the authors’ knowledge, no such studies have been conducted in South Africa.  
 
Clinical and experimental studies examining RV pacing observed that this technique caused a 
prolonged QRS duration, LV asymmetrical hypertrophy, dilatation, remodeling, mitral valve 
regurgitation, altered myocyte histology, reduced exercise capacity and coronary perfusion 
abnormalities. [5] Stimulation of the RV leads to an abnormal electrical and mechanical activation 
pattern by bypassing the physiological conducting system. [2,6] It alters the electrical activation of 
the LV and leads to dyssynchrony in LV contraction, resulting in impaired haemodynamic 
function.[7] 
 
RV pacing has been shown to cause heart failure symptoms with and without previous systolic 
LV dysfunction.[8] The Mode Selection Trial (MOST) showed an increased risk in hospitalisation 
in patients with RV pacing.[4,9] Unfortunately, the exact amount of RV apical pacing that 
negatively affects cardiac function remains unclear from the trials. The negative effects may be 
more pronounced in certain patient populations. Patients at risk of adverse effects of RV apical 
pacing include those with underlying conduction disease and patients with ischaemic heart 
disease. It has been suggested that patients who require pacing for a longer period of time and 
patients with depressed LV function at baseline are more susceptible to the deleterious effects of 
RV apical pacing.[4] 
 
All the literature is from studies done abroad and limitations to these studies were the small 
sample sizes and the absence of sequential echocardiographic monitoring of the LV function in 
each patient. [4,6,9,11] 
RV pacing is an important tool in the South African context, where resources and skilled staff 
are limited. This study attempted to elucidate the local South African experience by evaluating 
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the effects of RV pacing on LV function by assessing the EF on echocardiography in patients 
attending the pacemaker clinic at IALCH from 2003 to 2012. 
This study reviewed data collected from Inkosi Albert Luthuli Central Hospital (IALCH), which 
is a government hospital in Durban, KwaZulu-Natal (KZN), South Africa. The objective of the 
study was to evaluate the effects of RV pacing on LV function in a setting where the majority of 
patients requiring a permanent pacemaker receive single chamber RV apical pacing. The focus of 
this study was to assess the effect of RV pacing on LV function by assessing the ejection fraction 







Study Population – patients attending the pacemaker clinic at Inkosi Albert Luthuli Hospital 
(IALCH) from 2003 up to 2012. 
 
Sample Strategy – retrospective chart review.  The medical records of patients attending the 
pacemaker clinic over this period were reviewed. 
 
Sample size – The sample size was determined by the number of patients who met the inclusion 
criteria over the study period. Of the 465 patients screened, 35 were eligible for the study.  
 
Inclusion Criteria: 




Patients were excluded if they had coronary artery disease (CAD), unrepaired valvular heart 
disease, atrial fibrillation or dual chamber pacemakers. 
 
Procedure of RV pacing: 
RV pacing was performed through insertion of a lead in the subclavian vein with placement of 
the sensing and pacing electrode in the RV apex. 
 
Measurement of EF: 
EF was measured using 2D echocardiography and was calculated using the Simpson’s 
method.[12]  
LV dysfunction was defined as a left ventricular ejection fraction (LVEF) < 50%, as per the Heart 












The Intercooled Stata Version 13 Package was used to analyse the data. Descriptive statistics 
were used to present categorical variables. The mean and standard deviation were used to analyse 
continuous variables and the percentages of frequencies. Two group comparisons were made 
using a two sample t test. The two sample t test was used to calculate the change in the EF 
between baseline and follow-up. The Kruskal Wallis equality test was used to assess categorical 
variables when comparing more than two subgroups due to the small study numbers.  A p value 




Baseline patient characteristics 
 
Of 465 patients screened, 35 satisfied the inclusion criteria with pre- and post- pacemaker 
insertion EF and were eligible for the study. The baseline characteristics and comorbidity profile 
of the study population has been summarised in Table 1. The mean age was 62 years with a M:F 
ratio of 7:3. Almost half the subjects had a history of hypertension.  The most common indication 
(57%) for pacing was complete heart block, followed by second degree AV block (20%). Sick 
sinus syndrome and symptomatic bradycardia accounted for the remaining 22% of the patients. 
The VVI pacing mode was applied to the majority of patients. The average duration of pacing 
was 3.41 years.  
 
Gender and age did not have an effect on the EF. Similarly, hypertension, diabetes mellitus, 
dyslipidaemia and valvular heart disease had no significant impact on the LVEF.  Analysis of 




Table 1: Baseline characteristics of study patients and a correlation between patient variables  
 
 
Variables All Patients 
n = 35 
Mean change in 
EF(%) 
Standard deviation p  value 
 
Sex, n (%) 0.55 
- Male  11 (31%) -2.09 9.3  
- Female 24 (69%) -4.3 10.9  
 
Average age (years) 62 ±17.4   0.9 
- ≤ 45 6 -4 8.9  
- > 45 29 -3.6 10.8  
 
Indications for pacing, n (%) 0.35 
- Complete heart block  20 (57%) -3.4 10.3  
- Second degree AV block 7 (20%) -2.2 11.8  
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- Symptomatic bradycardia 4 (11%) -0.5 13.9  
- Sick sinus syndrome 4 (11%) -2.7 1.5  
 
Pacing Mode, n (%) 
- VVI 19(54%) -0.1 9.3  
- VVIR 13(37%) -8.3 11.1  
- VDD 3(9%) -6 6  
 
Average duration of pacing (years) 3.41    
 
Duration of pacing, n (%) 0.31 
- <1 year 12(34%) -0.5 6.8  
- 1-5 years 13 (37%) -5 12.2  
- >5 years 10 (29%) -5.7 11.3  
  
Co-morbidities, n (%) 
- Hypertension (HPT) 17(49%) -1.5 10.3 0.26 
- Diabetes Mellitus (DM) 7 (20%) -10.4 12.1 0.05 
- Dyslipidaemia 5 (14%) 1.6 4.9 0.22 
  
Valvular heart disease (repaired), n (%) 7 (20%) -1 10.2 0.45 
- Mitral valve replacement(MVR) 3 (9%)    
- Aortic valve replacement (AVR) 3 (9%)    
- Dual valve replacement (DVR) 1 (3%)    
 
VVI - single chamber ventricular pacing; VVIR - single chamber ventricular pacing, rate responsive;  
VDD - single chamber ventricular pacing with dual chamber sensing and inhibition  
 
Evaluation of Ejection Fraction 
 
Overall, amongst the 35 subjects, there was no significant change in mean EF from baseline EF 
(55%) to follow-up EF (52%), with an average change in EF of -3.6%, p = 0.10.  
 
 
Of the 35 study subjects, the study identified 8 patients with LV dysfunction at baseline. (Table 
2)  None of the 8 subjects were previously diagnosed with CAD and were therefore included in 
the study. These subjects showed a mean increase in ejection fraction of 5.4% between baseline 
and follow-up EF, compared to the remaining 27 with normal LV function at baseline who 
showed a mean decrease of 6.33%. The difference was statistically significant, p = 0.03. Of the 8 
patients, 2 had no change, and 1 showed a deterioration in EF between baseline and follow-up 
(Table 3).  
 
 

















1 43 56 13 SB 4 VVI HPT 
2 42 36 6 CHB 2 VDD Nil 
3 40 49 9 CHB 1 VVI HPT 
4 43 43 - AVB 4 VDD Nil 
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5 42 52 10 AVB 2 VVI MVR 
6 40 40 - CHB 1 VVI HPT,DM 
7 45 50 5 CHB 7 VVI AVR 
8 46 58 12 SB 1 VVI HPT/ 
LIPID 




Of the 35 subjects, 11 had evidence of LV dysfunction at follow-up, of whom 4 subjects had 
reduced EF at baseline (Table 3). As expected, these patients showed a statistically greater 
change in EF compared to patients with preserved LV function at follow-up, with p = 0.006. 
Although the cause for this deterioration was not clearly established it was not thought to be due 
to CAD.  The greatest change in EF (26%) between baseline and follow-up occurred in the 
subject with the  longest duration of pacing (9 years). 
 

















1 68 42 26 CHB 9 VVI DM 
2 42 36 6 CHB 2 VDD Nil 
3 59 37 22 AVB 2 VVIR Nil 
4 54 38 16 CHB 2 VVIR MVR 
5 54 35 19 CHB 1 VVIR Nil 
6 43 43 - AVB 4 VDD Nil 
7 40 40 - CHB 1 VVI DM, HPT 
8 54 48 6 CHB 6 VVIR HPT/ AVR 
9 55 45 10 CHB 8 VVI LIPID 
10 65 45 20 SB 3 VVIR HPT/ DM 
11 40 49 9 CHB 1 VVIR HPT 




RV pacing and the effect on LV function 
 
The main finding in this study was that RV pacing was accomplished without a significant 
change in EF in the majority of subjects. Age and gender had no impact on the change in EF. 
Hypertension, diabetes mellitus, dyslipidaemia, and valvular heart disease had no statistically 




An important finding in our study is that there was worsening of the EF in almost a quarter of the 
subjects. Although subjects included had no history of CAD, coronary angiograms were not 
performed in these subjects so it is not clear whether underlying CAD was present and could 
have accounted in part for deterioration in LV function. In the absence of overt coronary disease 
it appears that conventional RV pacing itself could be the mechanism since it has been shown 
that RV pacing produces a variable amount of ventricular dyssynchrony in most patients. Some 
studies have suggested that patients who require pacing for a longer period of time and patients 
with depressed LV function at baseline are more susceptible to the deleterious effects of RV 
pacing.[2,3]  
 
From the large pacing mode selection trials and observational studies, it has become apparent 
that RV pacing may be associated with a worse clinical outcome. The Danish Multicenter 
Randomized Trial on Single Atrial Lead Pacing versus Dual Chamber Pacing in Sick Sinus 
Syndrome (DANPACE) study showed no correlation between heart failure and RV pacing.[10] 
The Preventing Ventricular Dysfunction in Pacemaker Patients without Advanced Heart Failure 
(PREVENT – HF) study and The Biventricular Pacing for Atrio-ventricular Block to Prevent 
Cardiac Desynchronization (BIOPACE) study did not demonstrate statistically significant 
differences between biventricular and RV pacing.[9,11] The Biventricular versus Right Ventricular 
Pacing in Heart Failure Patients with Atrioventricular Block (BLOCK-HF) trial showed an 
improvement in cardiac function in patients with biventricular pacing.[10] 
 
Unfortunately, it remains unclear if there is an “optimal amount” of RV pacing and which 
patients are most susceptible to the deleterious effects of RV pacing. The negative effects may be 
related to the induction of ventricular dyssynchrony by RV apical pacing. Future studies are 
needed to address these remaining questions.[6] Additional analyses will perhaps identify cohorts 
of patients for whom biventricular pacing would confer a clear benefit. 
 
Limitations of the study 
 
The study was clearly limited by the low number of eligible patients out of 465 subjects who 
underwent pacemaker insertion. Because of the retrospective nature of the study there was a lack 
of complete datasets. Most patients who require a pacemaker do not routinely have a baseline 
echocardiographic assessment done prior to insertion of the pacemaker. The greatest limitation of 
the study was that EF was the only modality of LV functioning that was assessed. Evaluation of 
the EF on echocardiography is subjective and user dependent. This study also lacked control 
variables. 
 
Optimal pacing lead location 
 
The optimal pacing lead location for patients with a standard indication for ventricular pacing 
remains controversial.[4] From the larger pacing mode selection trials and the observational 
studies, there is a clear association between conventional RV pacing and the risk of adverse 
events. However, in daily clinical practice not all patients who receive RV pacing will experience 
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adverse events.[2] Moreover, the RV pacing site is not standardised and this poses a limitation in 
establishing the optimal lead location for pacing.  
 
Pacing from the RV outflow tract, septal pacing and direct His bundle pacing have been 
suggested as alternative pacing sites as they are in closer proximity to the normal conduction 
system and may result in less electrical activation delay and less mechanical dyssynchrony.[4] The 
potential benefit of pacing from non-right ventricle apical sites that can theoretically closely 
simulate the normal cardiac electrical activation sequence needs to be further explored. [12] 
 
This study has highlighted that we have no local or international guidelines to aid clinicians in 
monitoring patients after pacemaker insertion. This issue needs to be addressed as the indications 
for pacing are expanding. Furthermore, the lead location in the RV is not standardised or 
documented in patients clinical records. Since the lead location may play a role in the 
development of LV dysfunction, this needs to be monitored in an attempt to establish the optimal 
pacing site. Also, since the duration of pacing may play a role in the development of LV 
dysfunction. This issue needs to be explored in future studies. 
 
Conclusion  
This study showed no significant change in EF in the majority of subjects undergoing pacemaker 
insertion. While current literature shows that RV pacing is a safe, simple, and effective, we have 
shown that almost a quarter of the subjects had deterioration in the EF for which there was no 
clear explanation and therefore possibly due to RV pacing associated LV dysfunction. 
 
In the absence of clear monitoring guidelines, the authors recommend a standardised approach to 
all patients in whom RV pacing is considered appropriate, since RV pacing remains the most 
common site of lead placement, especially in the resource limited environment. Routine 
echocardiography to assess EF and more sensitive parameters of LV function such as tissue 
Doppler and strain imaging should be undertaken prior to insertion of the pacemaker or 
immediately thereafter.  Regular monitoring at standardised time intervals with repeated 
echocardiography to monitor LV function using sensitive techniques to detect early changes in 
LV segmental contractility. Clear documentation of indications for pacing, pacing lead location, 
pacing mode and co-morbidities should be included. The finding of deterioration in LV 
contractility should be accompanied by a careful search for a course including coronary disease 
and myocarditis as well as an reappraisal of the pacing mode in such cases.  
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Appendix 1: The final Study Protocol  
TITLE OF THE STUDY: 
The effects of right ventricular pacing on left ventricular function 
AIM OF THE STUDY: 
To determine the effect of right ventricular pacing on left ventricular function 
SPECIFIC OBJECTIVES: 
1. To determine if right ventricular pacing causes left ventricular dysfunction 
2. To determine if there is a correlation between left ventricular function at the time of 
pacemaker insertion and subsequent deterioration of left ventricle function 
BACKGROUND AND LITERATURE REVIEW: 
THE EFFECTS OF RIGHT VENTRICULAR PACING ON LEFT VENTRICULAR 
FUNCTION 
For more than 2 centuries, abnormalities of cardiac impulse formation and propagation have 
been recognized as potentially lethal causes of cardiovascular illness. The only effective 
treatment for symptomatic bradycardia caused sinus node dysfunction and atrioventricular 
block is cardiac pacing. (1)  
Cardiac pacing has been in existence for more than 50 years and during that time both clinical 
practice and an impressive body of research have proved its effectiveness objectively in terms 
of patient’s quality of life, morbidity and mortality. (2) 
Pacing of the right ventricle has become a standard, widespread procedure because it is 
convenient, easily accessible, well-tolerated, effective and usually provides appropriate 
sensing and threshold parameters. (1,3) With the appearance of new indications for cardiac 
pacing which includes patients with heart failure and left bundle branch block and the 
benefits of cardiac resynchronization therapy, the use of right ventricular pacing has come 
into the spotlight. In recent years, the potential detrimental effects of right ventricular pacing 
has been studied and left ventricular dyssynchrony has been shown to be a critical factor in 
causing left ventricular dysfunction. (4)   
Clinical and experimental studies examining right ventricle pacing observed that this 
technique caused prolonged QRS duration, left ventricle asymmetrical hypertrophy, 
dilatation, remodeling, mitral valve regurgitation, altered myocyte histology, reduced 
exercise capacity and coronary perfusion abnormalities.(5) Stimulation of the right ventricle 
leads to an abnormal electrical and mechanical activation pattern by bypassing the 
physiological conducting system. (3) It alters the electrical activation of the left ventricle and 
leads to dyssynchrony in left ventricular contraction, resulting in impaired haemodynamic 
function.(6) Dyssynchronous left ventricle activation during right ventricle pacing was 
described in small studies almost 30 years ago in mongrel dogs and in humans.(7)  
Studies have shown that right ventricular pacing does not produce the same amount of 
dyssynchrony in all patients. Some studies have suggested that patients who require pacing 
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for a longer period of time and patients with depressed left ventricular function at baseline are 
more susceptible to deleterious effects of right ventricular pacing.(1,4) Other studies have 
shown that right ventricular pacing causes heart failure symptoms in patients with and 
without previous systolic left ventricular dysfunction, but the mechanical consequences are of 
greater importance in individuals with severely impaired left ventricle function. (7)  
The optimal pacing lead location for patients with a standard indication for ventricular pacing 
remains controversial.(5)  From the larger pacing mode selection trials and the observational 
studies, there is a clear association between conventional right ventricular pacing and the risk 
of adverse events. However in daily clinical practice not all patients who receive right 
ventricular pacing will experience adverse events. (4) 
Pacing from the right ventricle outflow tract, septal pacing and direct His bundle pacing have 
been suggested as alternative pacing sites, they are in closer proximity to the normal 
conduction system and may result in less electrical activation delay and less mechanical 
dyssynchrony. (4) The potential benefit of pacing from non-right ventricle apical sites that can 
theoretically closely simulate the normal cardiac electrical activation sequence needs to be 
further explored. (8) 
Noting that right ventricular pacing causes a broad QRS complex and produces 
dyssynchrony, the question arises whether patients who do not meet the criteria for cardiac 
resynchronization therapy would benefit from biventricular pacing rather than right 
ventricular pacing only. Biventricular pacing has been primarily introduced to correct pre-
existing interventricular and intraventricular conduction delays, thereby improving 
ventricular function. Biventricular pacing has shown good results in patients with systolic 
heart failure. (1) Few clinical investigations have compared ventricular pacing sites in patients 
who do not meet the clinical requirements for cardiac resynchronization therapy. (5)  
Since the implantation of the first artificial pacemaker in 1958, these devices have become 
the treatment of choice in bradycardias. Despite its widespread use, only a few studies have 
looked at the long term effects of only right ventricular pacing on left ventricular function in 
patients with sinus node dysfunction or atrioventricular node dysfunction. (9)  Furthermore, the 
limitation to these studies were the small sample sizes and the absence of sequential 
echocardiographic variables of left ventricle function in each patient. To the best of our 
knowledge, no such studies have been done in South Africa. Thus there is a need for larger 
and longer term clinical trials to assess the effect of right ventricular pacing on left 
ventricular function and to address the effect of alternative pacing sites.  
Pacemaker technology has evolved over the years from right ventricular pacing to dual 
chamber and now cardiac resynchronization therapy. Various therapeutic options have been 
suggested in patients requiring a conventional pacemaker. The upgrade to cardiac 
resynchronization therapy may partially reverse the deleterious effects of right ventricular 
pacing. New pacing strategies and alternative right ventricular pacing sites may prevent the 
induction of left ventricle dyssynchrony and the deterioration of left ventricular function. (4)  
This study will review data collected from Inkhosi Albert Luthuli Central Hospital (IALCH), 
which a government hospital in Kwa-Zulu Natal. It will evaluate the effects of right 
ventricular pacing on left ventricle function in a setting where majority of the patients 
requiring a permanent pacemaker receive single chamber right ventricular pacing. It will 
assess whether there is a correlation between left ventricular function at the time of 
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STUDY DESIGN:   
Study Population – Patients attending Albert Luthuli Central Hospital (IALCH) Pacemaker 
Clinic from 2003 upto 2012  
Sample Strategy – Since this is a retrospective study, no sampling methods will be used.  
Statistical planning (variables/confounders) – left ventricular function, pre pacemaker 
insertion, post pacemaker insertion 
Sample size – Depends on the number of patients that meet the inclusion criteria after 
screening 
Inclusion criteria:  
1. Age above 18 years 
2. Patients with documented ejection fractions (EF) pre and post pacemaker insertion 
Exclusion Criteria:  
1. Coronary Artery Disease 
2. Valvular Heart Disease - unrepaired 
3. Atrial Fibrillation 
4. Patients with dual chamber pacemakers 
Data Collection methods and tools – this is a retrospective study and will use data that has 




Data analysis techniques and statistical analysis:  
The Statistical Package for Social Sciences (SPSS) version 21 will be used to analyze the 
data. 
Descriptive statistics, which include frequency and percentage distribution tables, charts and 
graphs will be used to present categorical variables. Measures of central tendency (mean, 
median and mode) and dispersion (variance, range and standard deviation) will be calculated 
for continuous variables. The paired samples t test will be used in determining the link 
between right ventricular pacing and left ventricular dysfunction by comparing the ejection 
fraction before and after pacemaker insertion. If the data are not normal distributed an 
equivalent non parametric test will be performed. 
STUDY LOCATION: 
Inkhosi Albert Luthuli Central Hospital (IALCH) – Kwa-Zulu Natal 
STUDY PERIOD:  
Patients attending the Pacemaker Clinic at IALCH from 2003 – upto 2012 
LIMITATIONS TO THE STUDY: 
1. This is a retrospective chart review and obtaining data maybe be difficult  
2. Most patients who require cardiac pacing do not routinely have a baseline 
echocardiograph prior to pacemaker insertion 
3. Study does not have controls 
4. Only one modality is being assessed – ejection fraction by echocardiography and this 
is subjective and user dependant 
ETHICAL CONSIDERATIONS: 
Patient confidentiality will be maintained at all times. Data will be collected on a password 
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CHB – complete heart block
AVB - 2nd degree atrioventricular block
SSS – sick sinus syndrome
SB – sinus bradycardia
Pacing Mode
VVI - single chamber ventricular pacing
VVIR - single chamber ventricular pacing, rate responsive




Baseline ejection fraction (BE)/ Follow-up ejection fraction (FE) - subgroups <50 or ≥50
1 = Yes
2 = No 
HPT – hypertension
DM – diabetes mellitus
LIPID – dyslipidaemia
VALVE REPAIR - valvular heart disease, repaired




0 = no valves
1 = mitral only
2 =  aortic only
3 =  mitral and aortic
